Merck Serono (Geneva, Switzerland), a division of Merck KGaA, will collaborate with Flamel Technologies (Lyon, France) to investigate the applicability of Flamel’s Medusa technology for the extended release of a therapeutic protein in Merck Serono’s portfolio.
Merck Serono (Geneva, Switzerland), a division of Merck KGaA, will collaborate with Flamel Technologies (Lyon, France) to investigate the applicability of Flamel’s Medusa technology for the extended release of a therapeutic protein in Merck Serono’s portfolio. Under the terms of the agreement, Merck Serono will make an upfront payment of €2 million to Flamel for investigating the therapeutic protein and Merck Serono will fund research and development efforts to be performed at Flamel.
